Redesign of NCI Clinical Trials System

The US National Cancer Advisory Board (NCAB) today formally accepted 22 strategic recommendations designed to reshape and enhance the National Cancer Institute's (NCI) clinical trials system.

The recommendations are included in a report "Restructuring the National Cancer Institute Clinical Trials Enterprise." The report was developed by the Clinical Trials Working Group (CTWG), a panel of 40 stakeholders established by NCI Director Dr. Andrew C. von Eschenbach in 2004. NCAB's vote to accept the report sets in motion several major steps to implement the recommendations that were first presented to NCAB in February. The result is a series of initiatives that includes an implementation plan and budget.

CTWG Chair Dr. James H. Doroshow, director of NCI's Division of Cancer Treatment and Diagnosis (DCTD), presented the report to NCAB. "With these steps, we hope to integrate the best of NCI's current clinical trial system into a cross-disciplinary enterprise," said Dr. Doroshow. For a detailed description of the CTWG recommendations go to http://integratedtrials.nci.nih.gov.

LymphomaInfo Social